Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Epizyme, Inc. (EPZM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.9300-0.1700 (-5.48%)
At close: 04:00PM EST
2.9300 0.00 (0.00%)
After hours: 06:03PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close3.1000
Open3.1400
Bid2.7500 x 4000
Ask3.3500 x 2900
Day's Range2.9100 - 3.1700
52 Week Range2.8300 - 13.3100
Volume2,203,961
Avg. Volume1,079,119
Market Cap298.79M
Beta (5Y Monthly)1.18
PE Ratio (TTM)N/A
EPS (TTM)-2.4730
Earnings DateFeb 21, 2022 - Feb 25, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.14
  • Business Wire

    Epizyme to Present New Data from Its Oncology Portfolio at 2021 American Society of Hematology Annual Meeting

    CAMBRIDGE, Mass., December 02, 2021--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets, today announced that new data from across its oncology portfolio will be presented at the upcoming 63rd American Society of Hematology (ASH) Annual Meeting, taking place from December 11 to 14, 2021 in Atlanta, Georgia. These presentations include trial design and data from combinatio

  • Business Wire

    Epizyme Announces Updates to Its Board of Directors

    CAMBRIDGE, Mass., November 18, 2021--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced two appointments to the Company’s Board of Directors: clinical oncology executive, Roy A. Beveridge, M.D., and international pharmaceutical and financial executive, Carol Stuckley, M.B.A. The Company today also announced that Andrew R. Allen, M.D., Ph.D., who has served on the Company's Board of Dir

  • Business Wire

    Epizyme to Participate in Jefferies London Healthcare Conference

    CAMBRIDGE, Mass., November 12, 2021--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that Grant Bogle, President and Chief Executive Officer of Epizyme, will present at the Jefferies London Healthcare Conference. A pre-recorded fireside chat will be available to play on demand starting at 3:00am EST (8:00am GMT) on November 18, 2021.

Advertisement
Advertisement